Assenagon Asset Management S.A. Sells 418,768 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Assenagon Asset Management reduced its Amneal Pharmaceuticals stake by 17.1%, selling 418,768 shares and retaining 2.03 million shares worth approximately $40.8 million.
• Amneal reported quarterly EPS of $0.30, exceeding analyst estimates of $0.24, on revenue of $796.2 million. The company issued fiscal 2026 EPS guidance of $0.96–$1.06.
• Analyst sentiment remains favorable, with nine Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $21 average price target; however, insiders sold 413,016 shares worth about $7.2 million in the past 90 days.

Assenagon Asset Management S.A. lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 17.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,026,781 shares of the company's stock after selling 418,768 shares during the quarter. Assenagon Asset Management S.A. owned about 0.63% of Amneal Pharmaceuticals worth $40,819,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMRX. Paralel Advisors LLC bought a new position in Amneal Pharmaceuticals during the second quarter worth $3,217,000. Renaissance Technologies LLC raised its stake in Amneal Pharmaceuticals by 1,586.8% during the 1st quarter. Renaissance Technologies LLC now owns 276,637 shares of the company's stock valued at $3,439,000 after purchasing an additional 260,237 shares during the last quarter. California State Teachers Retirement System raised its stake in Amneal Pharmaceuticals by 37.6% during the 1st quarter. California State Teachers Retirement System now owns 207,239 shares of the company's stock valued at $2,576,000 after purchasing an additional 56,588 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in Amneal Pharmaceuticals during the 1st quarter valued at $936,000. Finally, Sei Investments Co. boosted its holdings in Amneal Pharmaceuticals by 26.3% in the 1st quarter. Sei Investments Co. now owns 706,681 shares of the company's stock valued at $8,784,000 after purchasing an additional 147,249 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $19.18 on Friday. The stock has a market cap of $6.13 billion, a P/E ratio of 39.14, a PEG ratio of 2.25 and a beta of 1.22. The company's 50-day simple moving average is $18.55 and its 200 day simple moving average is $16.18. Amneal Pharmaceuticals, Inc. has a twelve month low of $9.77 and a twelve month high of $21.17. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.95 earnings per share for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the transaction, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the transaction, the executive vice president directly owned 35,171 shares of the company's stock, valued at approximately $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 in the last 90 days. 17.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on AMRX shares. The Goldman Sachs Group restated a "buy" rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an "overweight" rating in a report on Thursday, September 17th. Oppenheimer assumed coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $27.00 price objective for the company. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. Finally, JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $22.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.